Sîrbulescu Ruxandra F, Boehm Chloe K, Soon Erin, Wilks Moses Q, Ilieş Iulian, Yuan Hushan, Maxner Ben, Chronos Nicolas, Kaittanis Charalambos, Normandin Marc D, El Fakhri Georges, Orgill Dennis P, Sluder Ann E, Poznansky Mark C
Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Gordon Center for Medical Imaging, Nuclear Medicine and Molecular Imaging, Radiology Department, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Wound Repair Regen. 2017 Sep;25(5):774-791. doi: 10.1111/wrr.12584. Epub 2017 Oct 17.
Chronic wounds affect 12-15% of patients with diabetes and are associated with a drastic decrease in their quality of life. Here, we demonstrate that purified mature naive B220 /CD19 /IgM /IgD B cells improve healing of acute and diabetic murine wounds after a single topical application. B cell treatment significantly accelerated acute wound closure by 2-3 days in wild-type mice and 5-6 days in obese diabetic mice. The treatment led to full closure in 43% of chronic diabetic wounds, as compared to only 5% in saline-treated controls. Applying equivalent numbers of T cells or disrupted B cells failed to reproduce these effects, indicating that live B cells mediated pro-healing responses. Topically applied B cell treatment was associated with significantly reduced scar size, increased collagen deposition and maturation, enhanced angiogenesis, and increased nerve growth into and under the healing wound. β-III tubulin+ nerve endings in scars of wounds treated acutely with B cells showed increased relative expression of growth-associated protein 43. The improved healing associated with B cell treatment was supported by significantly increased fibroblast proliferation and decreased apoptosis in the wound bed and edges, altered kinetics of neutrophil infiltration, as well as an increase in TGF-β and a significant reduction in MMP2 expression in wound granulation tissue. Our findings indicate that the timeline and efficacy of wound healing can be experimentally manipulated through the direct application of mature, naive B cells, which effectively modify the balance of mature immune cell populations within the wound microenvironment and accelerate the healing process.
慢性伤口影响12%至15%的糖尿病患者,与他们的生活质量急剧下降相关。在此,我们证明,单次局部应用纯化的成熟幼稚B220⁺/CD19⁺/IgM⁺/IgD⁺ B细胞可改善急性和糖尿病小鼠伤口的愈合。B细胞治疗使野生型小鼠的急性伤口闭合显著加速2至3天,肥胖糖尿病小鼠加速5至6天。与生理盐水处理的对照组仅5%相比,该治疗使43%的慢性糖尿病伤口完全闭合。应用等量的T细胞或破碎的B细胞未能重现这些效果,表明活B细胞介导了促愈合反应。局部应用B细胞治疗与瘢痕大小显著减小、胶原沉积和成熟增加、血管生成增强以及愈合伤口内和下方神经生长增加相关。急性用B细胞处理的伤口瘢痕中的β-III微管蛋白⁺神经末梢显示生长相关蛋白43的相对表达增加。伤口床和边缘的成纤维细胞增殖显著增加、细胞凋亡减少、中性粒细胞浸润动力学改变,以及伤口肉芽组织中TGF-β增加和MMP2表达显著降低,支持了与B细胞治疗相关的愈合改善。我们的研究结果表明,通过直接应用成熟的幼稚B细胞,可以在实验中操纵伤口愈合的时间进程和疗效,成熟的幼稚B细胞可有效改变伤口微环境中成熟免疫细胞群体的平衡并加速愈合过程。